| Package | hl7.fhir.uv.pddi |
| Resource Type | ValueSet |
| Id | valueset-rimexolone-exclude |
| FHIR Version | R4 |
| Source | http://hl7.org/fhir/uv/pddi/https://build.fhir.org/ig/HL7/PDDI-CDS/ValueSet-valueset-rimexolone-exclude.html |
| URL | http://hl7.org/fhir/uv/pddi/ValueSet/valueset-rimexolone-exclude |
| Version | 1.0.0-ballot |
| Status | draft |
| Date | 2018-07-02 |
| Name | Valueset_rimexolone_exclude |
| Title | Exclude Rimexolone Medications Value Set |
| Realm | uv |
| Authority | hl7 |
| Description | ValueSet containing drug identifiers to exclude. Criteria is explicitly stating topical, gel, cream, ointment, otic, or ophthalmic formulations. |
| Purpose | To refine valueset for Warfarin + NSAID PDDI-CDS |
| Copyright | (copyright expectations unknown) |
No resources found
| CodeSystem | |
| rxnorm | RxNorm |
Note: links and images are rebased to the (stated) source
Generated Narrative: ValueSet valueset-rimexolone-exclude
http://www.nlm.nih.gov/research/umls/rxnorm| Code | Display |
| 207446 | rimexolone 10 MG/ML Ophthalmic Suspension [Vexol] |
| 365826 | rimexolone Ophthalmic Suspension [Vexol] |
| 199115 | rimexolone 10 MG/ML Ophthalmic Suspension |
| 379299 | rimexolone Ophthalmic Suspension |
| 1157440 | rimexolone Ophthalmic Product |
| 1188083 | Vexol Ophthalmic Product |
{
"resourceType": "ValueSet",
"id": "valueset-rimexolone-exclude",
"text": {
"status": "generated",
"div": "<!-- snip (see above) -->"
},
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg",
"valueCode": "cds"
}
],
"url": "http://hl7.org/fhir/uv/pddi/ValueSet/valueset-rimexolone-exclude",
"version": "1.0.0-ballot",
"name": "Valueset_rimexolone_exclude",
"title": "Exclude Rimexolone Medications Value Set",
"status": "draft",
"experimental": true,
"date": "2018-07-02",
"publisher": "HL7 Clinical Decision Support Workgroup",
"contact": [
{
"telecom": [
{
"system": "url",
"value": "http://hl7.org/Special/committees/dss"
}
]
}
],
"description": "ValueSet containing drug identifiers to exclude. Criteria is explicitly stating topical, gel, cream, ointment, otic, or ophthalmic formulations.",
"jurisdiction": [
{
"coding": [
{
"system": "http://unstats.un.org/unsd/methods/m49/m49.htm",
"code": "001"
}
]
}
],
"purpose": "To refine valueset for Warfarin + NSAID PDDI-CDS",
"copyright": "(copyright expectations unknown)",
"compose": {
"include": [
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"concept": [
{
"code": "207446",
"display": "rimexolone 10 MG/ML Ophthalmic Suspension [Vexol]"
},
{
"code": "365826",
"display": "rimexolone Ophthalmic Suspension [Vexol]"
},
{
"code": "199115",
"display": "rimexolone 10 MG/ML Ophthalmic Suspension"
},
{
"code": "379299",
"display": "rimexolone Ophthalmic Suspension"
},
{
"code": "1157440",
"display": "rimexolone Ophthalmic Product"
},
{
"code": "1188083",
"display": "Vexol Ophthalmic Product"
}
]
}
]
}
}